Search - tctmd.com

Displaying 21 - 40 of 46

Sort: Relevancy | Date

Presentation THT 2025

Emerging Therapies Targeting Inflammation and Metabolic Dysfunction in Heart Failure

Presenter: Mark Petrie

February 11, 2025

Presentation THT 2025

Technologies Targeting Acute Limb Ischemia in Cardiogenic Shock

Presenter: Navin Kapur

February 11, 2025

Presentation TCT 2024

Impact of Delays in Diagnosis and Treatment: Join the AHA TARGET AS Program!

Presenter: Brian Lindman

October 30, 2024

Presentation TCT 2024

CON: Too Early or Too Risky

Presenter: Kevin Bainey

October 29, 2024

Presentation TCT 2024

PRO: Time is Now: Targeting Acute Inflammation and Residual Inflammatory Risk

Presenter: Vijay Kunadian

October 29, 2024

Presentation TCT 2024

Role of Inflammation in Coronary Heart Disease: Why Does it Matter

Presenter: Deepak Bhatt

October 29, 2024

Presentation TCT 2024

Putting it Together: New Systems of Care to Optimize Risk Factors Targets

Presenter: Amit Khera

October 29, 2024

Presentation TCT 2024

Lipid-Lowering Therapies for High-Risk Patients: Act Early and Target Aggressively

Presenter: Marc Bonaca

October 28, 2024

Presentation TCT 2024

TCT 28: Target Vessel Revascularization and Amputation After Chronic Limb-Threatening Ischemia Across Race Among Medicare Beneficiaries

Presenter: Joseph Kim

October 27, 2024

Presentation Interventional Complications 2024

Is Carotid Access a Percutaneous Target?

Presenter: James McCabe

August 02, 2024

Presentation NY Valves 2024

A New Class of TAVR, A New Design Target

Presenter: Christopher Meduri

June 05, 2024

Presentation ACC 2024

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Presenter: David E. Kandzari

April 08, 2024

Presentation THT 2024

A Novel Study Design, Termed Molecular Triangulation, That Leverages Biologic Similarities Across Seemingly Different Shock Phenotypes In Order to Identify Novel Druggable Targets and Pathophysiologic Mechanisms.

Presenter: Thomas Hanff

March 06, 2024

Presentation ACC 2022

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

April 04, 2022

Presentation TCT 2021

TARGET AC 4-year Results & Deep Dive in Diabetes Subgroup

Presenter: Alexandra Lansky

November 06, 2021

Presentation ACC 2019

Chemical Renal Denervation with Alcohol: The Post-Market Study Data and The Target BP Program

Presenter: Horst Sievert

March 18, 2019

Presentation EuroPCR 2018

TARGET AC A prospective multicenter randomized post-market trial evaluating a novel Cobalt Chrome Rapamycin Drug Eluting Stent

Presenter: Andreas Baumbach

May 25, 2018

Presentation TCT 2017

TCT 13: A First-in-Man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease (FUTURE-I) - One-Year Clinical and Imaging Outcomes

Presenter: Stephan Achenbach, Jacques J. Koolen, Bo Xu

October 31, 2017

Presentation TCT 2016

TCT 52: Proportion and Morphological Features of Restenosis Lesions With Acute Coronary Syndrome in Different Timings of Target Lesion Revascularization After Sirolimus-Eluting Stent Implantation

Presenter: Michael J. Cowley, Franz-Josef Neumann, Shunsuke Kubo

October 31, 2016

Presentation

Cell-Penetrating Pepducin Therapy Targeting PAR-1 in Subjects With CAD

Presenter: PA. Gurbel

December 16, 2015

Advertisement

Emerging Therapies Targeting Inflammation and Metabolic Dysfunction in Heart Failure

Technologies Targeting Acute Limb Ischemia in Cardiogenic Shock

Impact of Delays in Diagnosis and Treatment: Join the AHA TARGET AS Program!

CON: Too Early or Too Risky

PRO: Time is Now: Targeting Acute Inflammation and Residual Inflammatory Risk

Role of Inflammation in Coronary Heart Disease: Why Does it Matter

Putting it Together: New Systems of Care to Optimize Risk Factors Targets

Lipid-Lowering Therapies for High-Risk Patients: Act Early and Target Aggressively

TCT 28: Target Vessel Revascularization and Amputation After Chronic Limb-Threatening Ischemia Across Race Among Medicare Beneficiaries

Is Carotid Access a Percutaneous Target?

A New Class of TAVR, A New Design Target

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

A Novel Study Design, Termed Molecular Triangulation, That Leverages Biologic Similarities Across Seemingly Different Shock Phenotypes In Order to Identify Novel Druggable Targets and Pathophysiologic Mechanisms.

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

TARGET AC 4-year Results & Deep Dive in Diabetes Subgroup

Chemical Renal Denervation with Alcohol: The Post-Market Study Data and The Target BP Program

TARGET AC A prospective multicenter randomized post-market trial evaluating a novel Cobalt Chrome Rapamycin Drug Eluting Stent

TCT 13: A First-in-Man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease (FUTURE-I) - One-Year Clinical and Imaging Outcomes

TCT 52: Proportion and Morphological Features of Restenosis Lesions With Acute Coronary Syndrome in Different Timings of Target Lesion Revascularization After Sirolimus-Eluting Stent Implantation

Cell-Penetrating Pepducin Therapy Targeting PAR-1 in Subjects With CAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content